BioSpace News Archive

- In previously reported positive topline results from pivotal Phase 2/3 clinical trial in December 2019, vazegepant achieved statistical superiority to placebo on the co-primary regulatory endpoints of pain freedom and freedom from most bothersome symptom at 2 hours - Vazegepant is a third generation, high affinity, selective and structurally unique, small molecule CGRP receptor antagonist from Biohaven’s NOJECTION™ Migraine Platform and the only intranasal CGRP receptor antagonist in

Arch Therapeutics, Inc. today announced that the U.S. Food and Drug Administration (FDA) provided clearance to market AC5 ® Topical Gel that is manufactured using an additional supplier and additional manufacturing processes. AC5 Topical Gel is to be used in the management of partial and full-thickness wounds, such as pressu

LifeSci Acquisition Corp. (NASDAQ: LSACU), a blank check company targeting the biopharma, medical technology, digital health and healthcare services sectors, today announced the underwriters of its previously announced public offering of units partially exercised their over-allotment option, resulting in the issuance of an additional 563,767 units. The units are listed on the NASDAQ Capital Market (“NASDAQ”) and began trading under the symbol “LSAC

Predictive Oncology Inc. (NASDAQ: POAI) (“Predictive Oncology” or “the Company”), a data and artificial intelligence (“AI”) driven discovery services company that provides predictive models of tumor drug response to improve clinical outcomes for patients, today announced that on March 19, 2020, the Company closed on its previously announced private offering of common stock and warrants resulting in gross proceeds to the Company of $3,498,612.

Tetra Bio-Pharma Inc . ( today would like to announce that it has ensured that all of its employees work under conditions that comply with federal and provincial public health recommendations. Additionally, following the completion of its $17.8 M financing in February and early March, the Company is in a good position to maintain it

AbbVie (NYSE: ABBV), today announced the VIALE-A (M15-656) trial of VENCLEXTA® (venetoclax) in combination with azacitidine versus azacitidine in combination with placebo met its dual primary endpoints of statistically significant improvement of overall survival (OS) and composite complete remission rate (CR + CRi) for patients with previously-untreated acute myeloid leukemia (AML) who are ineligible for intensive chemotherapy

BrainsWay Ltd. today reported financial results for the quarter and full-year ended December 31, 2019, and provided an operational update. “We are very pleased with our solid fourth quarter and full-year 2019 results. Our strong results are indicative of the continued growing demand for our deep transcranial ma

CNS Pharmaceuticals, Inc. (NASDAQ: CNSP) (“CNS” or the “Company”), a biopharmaceutical company primarily specializing in the development of novel treatments for cancers of the brain and central nervous system, announces it has entered into an agreement with WPD Pharmaceuticals Inc. (CSE: WBIO) for the development of several preclinical d

Prometheus Biosciences, Inc., Inc. (“Prometheus”), a biopharmaceutical company committed to the discovery, development, and commercialization of a broad portfolio of novel precision therapeutics and diagnostics for patients living with unmet needs in gastroenterology and autoimmune diseases, announced today that it has launched the Monitr™ COVID-19 Assistance Program (M.C.A.P.) to provide adult Crohn’s disease (CD) patients with access to this valuable test.

Akebia Therapeutics, Inc. (Nasdaq: AKBA), a biopharmaceutical company focused on the development and commercialization of therapeutics for people living with kidney disease, today announced that the Company will present three posters at the upcoming National Kidney Foundation (NKF) 2020 Spring Clinical Meetings Live Virtual Conference.